Should routine cardiovascular screening be made mandatory before and during CDK4/6 inhibitor therapy in women with breast cancer? ##Reference## Leenaerts V, Cauwenberghs N, Wildiers H, et al. Cardiovascular event burden in women with breast cancer treated with CDK4/6 inhibitors: a retrospective matched cohort study. Cardio-Oncology. 2026.## ##Disclaimer## The content provided on Docplexus is intended for educational purposes only.
While we strive to ensure its accuracy, we make no explicit or implied warranties about the information's suitability, reliability, or adequacy, including data visualization elements and graphics. We do not endorse any medical treatment, product, ideas, or service, including content from our industry partners. We do not associate with the views of any individual, community, organization, industry partner, or political party. Unauthorized use, reproduction, or…
